Standardised uptake value (SUV) Archives

Tag: Standardised uptake value (SUV)

It was designed to be a simplistic method to quantify uptake as opposed to true quantification through compartmental and kinetic modeling. An SUV of 2.5 or higher is generally considered to be indicative of malignant tissue; however, there has been a wide range of SUVs reported for similar diseases. It is important to recognize that an SUV around 2.5 can be measured in non-malignant regions. Conversely, small tumors can also exhibit maximum SUV of <2.5.

NOTE: Any measurements quoted may not apply to SSTR PET or NET. See your specialist for further info.

09 Jul 2024

By Ronny Allan

3 Comments

Understanding your Somatostatin Receptor (SSTR) PET/CT Scan Results

Patient Advocacy18F-FDG, 64Cu-DOTATATE, CT scan, False negative, False positive, Ga68 PET/CT, Octreotide scan, PET Scan, Physiological uptake, Scanxiety, Somatostatin receptor scintigraphy (SRS), Somatostatin receptors (SSTR), SSTR-PET, Standardised uptake value (SUV)

Background In my online patient group, there is constant discussion about the meaning of both pictures and words on scan reports. The one that seems to cause the most confusion is PET scans, mainly somatostatin receptor (SSTR) PETs such as Ga68 and Cu64 variants. Worth adding that it's the addition of a nuclear tracer that makes PETs seem different. Generally speaking, the PET hardware is essentially the same. Most have a built-in CT scan, much less frequently an MRI scan. Confusion is often triggered by healthcare system processes where the patient receives the report before the appointment to discuss the…

20 Jun 2024

By Ronny Allan

21 Comments

Somatostatin Receptors

Awareness, TreatmentCarcinoid syndrome, Carcinoid tumour, Gamma camera, Hormones, Lanreotide, Octreotide, Octreotide scan, Pasireotide, Peptide receptor radionuclide therapy (PRRT), PRRT, Radiolabelled somatostatin analogue, SIGNIFOR® (Pasireotide), Somatostatin analogues, Somatostatin receptors (SSTR), Standardised uptake value (SUV), Yttrium 90 (Y90)

Don't understand Somatostatin Receptors? Join the club! I got my head around the term 'Somatostatin' and 'Somatostatin Analogues' some time ago but the term 'Somatostatin Receptor' (SSTR) is still a bit of a mystery. SSTRs do come up in conversation quite often and I'm fed up of nodding sagely hoping it will eventually become clear! On analysis it looks like a technical subject - and therefore a challenge. I've taken a logical approach working from 'Somatostatin' to 'Somatostatin Analogue' before commencing on the 'receptor' bit. It is intentionally brief and (hopefully) simplistic! Somatostatin It's important to understand this hormone and…

13 Dec 2020

By Ronny Allan

2 Comments

Selecting patients and the Challenges of Evaluating Response to PRRT in GEPNETs: The Present and the Future

Clinical Trials and Research, Patient Advocacy, TreatmentAdvanced neuroendocrine cancer, Biomarker, Ga68 PET/CT, Gastro-entero-pancreatic neuroendocrine tumour (GEP-NET), Lu-177, Lutathera, Molecular markers, NETest, Neuroendocrine tumour (NET), Peptide receptor radionuclide therapy (PRRT), PRRT, Standardised uptake value (SUV), Tumour marker

Share on facebook Facebook Share on twitter Twitter Share on pinterest Pinterest Share on whatsapp WhatsApp Share on email Email Fascinating article from the Italian NET scientific community. This article is more than just what the title says, it provides overviews on many facets of NETs including markers, scans and PRRT itself. It covers how to select patients for PRRT in the first place, i.e. who is most likely to get a good response to this treatment and then look at how to track and assess that response. The important thing I gathered from reading is that none of this…